Circulating angiogenic factors and HIV among pregnant women in Zambia: a nested case–control study

Table 3 Associations between adverse outcomes and biomarker concentrations

	Odds Ratio^ǂ	95% CI	adjusted Odds Ratio^ǂ^	adjusted 95% CI^
Preeclampsia (n = 4, missing = 59)
sEng	1.02	0.71 – 1.45	1.06	0.70 – 1.60
PlGF	1.00	0.68 – 1.45	1.02	0.68 – 1.53
sFLT-1	1.20	0.81 – 1.77	1.33	0.86 – 2.05
Preterm Birth (n = 11, missing = 17)
sEng	0.96	0.77 – 1.19	1.00	0.79 – 1.27
PlGF	0.71	0.54 – 0.93	0.73	0.55 – 0.97
sFLT-1	0.81	0.64 – 1.03	0.89	0.69 – 1.15
SGA (n = 17, missing = 24)
sEng	1.04	0.87 – 1.26	0.99	0.80 – 1.22
PlGF	1.05	0.87 – 1.26	1.05	0.86 – 1.29
sFLT-1	0.87	0.72 – 1.05	0.92	0.74 – 1.14
Stillbirth (n = 5, missing = 19)
sEng	0.87	0.63 – 1.20	0.93	0.64 – 1.36
PlGF	0.64	0.41 – 1.01	0.71	0.44 – 1.13
sFLT-1	0.66	0.43 – 1.02	0.78	0.49 – 1.24
Adverse Birth Outcome* (n = 12, missing = 19)
sEng	0.92	0.75 – 1.14	0.96	0.76 – 1.21
PlGF	0.68	0.52 – 0.90	0.70	0.53 – 0.93
sFLT-1	0.78	0.61 – 0.99	0.86	0.67 – 1.12

ǂCoefficient is for one decile increase in the analyte
*Adverse birth outcome is a combined variable including stillbirth and gestational age of <37 weeks at delivery
^Adjusted for maternal BMI at enrollment, parity, and HIV status

ISSN: 1471-2393